252 related articles for article (PubMed ID: 28651817)
41. Angiogenesis as a target for the treatment of ovarian cancer.
Shaw D; Clamp A; Jayson GC
Curr Opin Oncol; 2013 Sep; 25(5):558-65. PubMed ID: 23942301
[TBL] [Abstract][Full Text] [Related]
42. Therapeutic potential of the anti-diabetic agent metformin in targeting the skin cancer stem cell diaspora.
Reddi A; Powers MA; Dellavalle RP
Exp Dermatol; 2014 May; 23(5):345-6. PubMed ID: 24521225
[TBL] [Abstract][Full Text] [Related]
43. Bevacizumab in the treatment of ovarian cancer.
Han ES; Monk BJ
Expert Rev Anticancer Ther; 2007 Oct; 7(10):1339-45. PubMed ID: 17944559
[TBL] [Abstract][Full Text] [Related]
44. MicroRNA-136 inhibits cancer stem cell activity and enhances the anti-tumor effect of paclitaxel against chemoresistant ovarian cancer cells by targeting Notch3.
Jeong JY; Kang H; Kim TH; Kim G; Heo JH; Kwon AY; Kim S; Jung SG; An HJ
Cancer Lett; 2017 Feb; 386():168-178. PubMed ID: 27887917
[TBL] [Abstract][Full Text] [Related]
45. CRLX101, an investigational camptothecin-containing nanoparticle-drug conjugate, targets cancer stem cells and impedes resistance to antiangiogenic therapy in mouse models of breast cancer.
Conley SJ; Baker TL; Burnett JP; Theisen RL; Lazarus D; Peters CG; Clouthier SG; Eliasof S; Wicha MS
Breast Cancer Res Treat; 2015 Apr; 150(3):559-67. PubMed ID: 25833208
[TBL] [Abstract][Full Text] [Related]
46. Angiogenesis in ovarian cancer.
Brown MR; Blanchette JO; Kohn EC
Baillieres Best Pract Res Clin Obstet Gynaecol; 2000 Dec; 14(6):901-18. PubMed ID: 11141340
[TBL] [Abstract][Full Text] [Related]
47. Therapeutic Strategies for Targeting Ovarian Cancer Stem Cells.
Yang W; Kim D; Kim DK; Choi KU; Suh DS; Kim JH
Int J Mol Sci; 2021 May; 22(10):. PubMed ID: 34064635
[TBL] [Abstract][Full Text] [Related]
48. What is the risk of bowel perforation associated with bevacizumab therapy in ovarian cancer?
Han ES; Monk BJ
Gynecol Oncol; 2007 Apr; 105(1):3-6. PubMed ID: 17383545
[No Abstract] [Full Text] [Related]
49. In vitro and in vivo antiproliferative activity of metformin on stem-like cells isolated from spontaneous canine mammary carcinomas: translational implications for human tumors.
Barbieri F; Thellung S; Ratto A; Carra E; Marini V; Fucile C; Bajetto A; Pattarozzi A; Würth R; Gatti M; Campanella C; Vito G; Mattioli F; Pagano A; Daga A; Ferrari A; Florio T
BMC Cancer; 2015 Apr; 15():228. PubMed ID: 25884842
[TBL] [Abstract][Full Text] [Related]
50. Vascular determinants of cancer stem cell dormancy--do age and coagulation system play a role?
Rak J; Milsom C; Yu J
APMIS; 2008; 116(7-8):660-76. PubMed ID: 18834410
[TBL] [Abstract][Full Text] [Related]
51. Targeted trials in ovarian cancer.
Ledermann JA; Raja FA
Gynecol Oncol; 2010 Oct; 119(1):151-6. PubMed ID: 20591473
[TBL] [Abstract][Full Text] [Related]
52. Targeted agents in ovarian cancer.
Kristedja TS; Morgan RJ; Cristea M
Womens Health (Lond); 2010 Sep; 6(5):679-94. PubMed ID: 20887168
[TBL] [Abstract][Full Text] [Related]
53. Selective inhibition of breast cancer stem cells by gold nanorods mediated plasmonic hyperthermia.
Xu Y; Wang J; Li X; Liu Y; Dai L; Wu X; Chen C
Biomaterials; 2014 May; 35(16):4667-77. PubMed ID: 24630839
[TBL] [Abstract][Full Text] [Related]
54. [The role of cancer stem cells in progressive growth and resistance of ovarian cancer: true or fiction?].
Bar JK; Grelewski P; Lis-Nawara A; Drobnikowska K
Postepy Hig Med Dosw (Online); 2015 Sep; 69():1077-86. PubMed ID: 26400893
[TBL] [Abstract][Full Text] [Related]
55. A medicinal chemistry perspective on salinomycin as a potent anticancer and anti-CSCs agent.
Antoszczak M
Eur J Med Chem; 2019 Feb; 164():366-377. PubMed ID: 30611056
[TBL] [Abstract][Full Text] [Related]
56. Pulmonary hypertension in two patients treated with bevacizumab for recurrent ovarian cancer.
Liotta M; Rose PG; Escobar PF
Gynecol Oncol; 2009 Nov; 115(2):308-9. PubMed ID: 19740533
[No Abstract] [Full Text] [Related]
57. Cancer stem cells and angiogenesis.
Zhao Y; Bao Q; Renner A; Camaj P; Eichhorn M; Ischenko I; Angele M; Kleespies A; Jauch KW; Bruns C
Int J Dev Biol; 2011; 55(4-5):477-82. PubMed ID: 21732274
[TBL] [Abstract][Full Text] [Related]
58. Angiogenesis in normal and neoplastic ovaries.
Ramakrishnan S; Subramanian IV; Yokoyama Y; Geller M
Angiogenesis; 2005; 8(2):169-82. PubMed ID: 16211363
[TBL] [Abstract][Full Text] [Related]
59. Metformin and prostate cancer stem cells: a novel therapeutic target.
Mayer MJ; Klotz LH; Venkateswaran V
Prostate Cancer Prostatic Dis; 2015 Dec; 18(4):303-9. PubMed ID: 26215782
[TBL] [Abstract][Full Text] [Related]
60. Tumor T1 Relaxation Time for Assessing Response to Bevacizumab Anti-Angiogenic Therapy in a Mouse Ovarian Cancer Model.
Ravoori MK; Nishimura M; Singh SP; Lu C; Han L; Hobbs BP; Pradeep S; Choi HJ; Bankson JA; Sood AK; Kundra V
PLoS One; 2015; 10(6):e0131095. PubMed ID: 26098849
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
